DSM’s Patricia Malarkey appointed as new Chair of EuropaBio
PRESS RELEASE
June 23, 2022, Brussels - Today, EuropaBio’s General Assembly confirmed the appointment of Patricia Malarkey as the new Chair of the association. Patricia Malarkey is the global Chief Science Officer at DSM.
Commenting on her appointment, Patricia Malarkey highlighted: ‘I am delighted to take on the role of Chair of the Board at EuropaBio at a time of global transformation where biotechnology plays a key role to achieve a more sustainable and healthier society. EuropaBio has the advantage of being able to look across biotechnology sectors and champion innovation. Its members encompass companies of all sizes plus the regional and national associations that create the fabric of Europe. Now, more than ever before, these voices need to join together to help Europe build the innovation framework for the benefit of all and to support the EU to deliver on its Green Deal ambitions. I would like to thank Andrew Topen for his leadership of EuropaBio over the last two years especially in building a solid advocacy and visibility of the organisation.’
Dr Claire Skentelbery, Director General of EuropaBio added ‘Biotechnology is accelerating its impact across sectors, especially in the transition onto a post-fossil fuel world for manufacture and sustainable agriculture. DSM represents the significant focus that multi-national companies now have for biotechnology and its own transformation reflects the fast growing investment and race for global competitiveness. We are delighted that DSM will lead EuropaBio into a new era for economic growth from biotech.’
Mrs Malarkey will take on the new role with immediate effect for a two year mandate.
Commenting on her appointment, Patricia Malarkey highlighted: ‘I am delighted to take on the role of Chair of the Board at EuropaBio at a time of global transformation where biotechnology plays a key role to achieve a more sustainable and healthier society. EuropaBio has the advantage of being able to look across biotechnology sectors and champion innovation. Its members encompass companies of all sizes plus the regional and national associations that create the fabric of Europe. Now, more than ever before, these voices need to join together to help Europe build the innovation framework for the benefit of all and to support the EU to deliver on its Green Deal ambitions. I would like to thank Andrew Topen for his leadership of EuropaBio over the last two years especially in building a solid advocacy and visibility of the organisation.’
Dr Claire Skentelbery, Director General of EuropaBio added ‘Biotechnology is accelerating its impact across sectors, especially in the transition onto a post-fossil fuel world for manufacture and sustainable agriculture. DSM represents the significant focus that multi-national companies now have for biotechnology and its own transformation reflects the fast growing investment and race for global competitiveness. We are delighted that DSM will lead EuropaBio into a new era for economic growth from biotech.’
Mrs Malarkey will take on the new role with immediate effect for a two year mandate.
